Canoa ProSolus Press Release

Canoa Inc. to Acquire Privately-Held ProSolus Inc.

Canoa Inc. to Acquire Privately-Held ProSolus Inc., Accelerating Transdermal Patch Drug Delivery Product Development MIAMI, Florida, August 02, 2019 – Canoa Inc. (“Canoa”), a Delaware corporation with a focus on healthcare and pharmaceuticals, today announced that it has agreed to acquire ProSolus® Inc. (“ProSolus”), from Mission Pharmacal® Company, in an all-cash transaction. ProSolus is a…

Details
pharmaceutical coater

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery TechnologyParent company, Mission Pharmacal, expands commitment to patch technology with significant investments in manufacturing and commercial team. Transdermal patch production line at ProSolus, Inc. in Miami Juan Mantelle, ProSolus Chief Operating Officer and Chief Scientific Officer MIAMI, Fla. (April 25, 2017) – ProSolus, Inc. (“ProSolus”) is doubling…

Details
Prosolus pharmaceuticals

Mission Pharmacal Acquires ProSolus Pharmaceuticals

Acquisition adds cutting-edge expertise in transdermal drug development and manufacturing SAN ANTONIO, TX — Effective May 29, 2015, Mission Pharmacal Company (“Mission”) has acquired the assets of ProSolus Pharmaceuticals LP headquartered in Miami, Fla. Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug…

Details